ΑD)			

Award Number: DAMD17-00-1-0220

TITLE: Prevention and Treatment of Spontaneous Mammary Carcinoma

with Dendritic Tumor Fusion Cell Vaccine

PRINCIPAL INVESTIGATOR: Jianlin Gong, M.D.

CONTRACTING ORGANIZATION: Dana Farber Cancer Institute

Boston, Massachusetts 02115

REPORT DATE: July 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND					
	July 2001	Annual (1 Jul					
4. TITLE AND SUBTITLE	5. FUNDING NUMBERS DAMD17-00-1-0220						
Prevention and Treatment of Spontaneous Mammary Carcinoma DAMD17-00-1-0220 with Dendritic Tumor Fusion Cell Vaccine							
with Dendritte ramor ra	asion ceri vaccine						
6. AUTHOR(S)							
Jianlin Gong, M.D.							
7. PERFORMING ORGANIZATION NA	1	IG ORGANIZATION					
Dana Farher Cancer Institute Boston, Massachusetts 02115			REPORT NUMBER				
Boston, Wassachusetts 02113							
E-Mail:							
9. SPONSORING / MONITORING AG	GENCY NAME(S) AND ADDRESS(ES)	10. SPONSORING / MONITORING AGENCY REPORT NUMBER				
U.S. Army Medical Research and	Materiel Command		AGENCY REPORT NOWBER				
Fort Detrick, Maryland 21702-50							
Torr Borrow, Wary and 21762 00			1				
				•			

11. SUPPLEMENTARY NOTES							
12a. DISTRIBUTION / AVAILABILITY		12b. DISTRIBUTION CODE					
	- 1 1 1 1 1 1 TT. T	2 2					
Approved for Public Rel	ease; Distribution Unl	imited.					
Approved for Public Rel	ease; Distribution Unl	imited					
Approved for Public Rel	ease; Distribution Unl.	imited					
Approved for Public Rel 13. ABSTRACT (Maximum 200 Work		imited					
		imited					
		imited					
13. ABSTRACT (Maximum 200 Work	ds)		alle. The fuei				
13. ABSTRACT (Maximum 200 Word We have developed a va	ds) accine based on the fusions	of DC with tumor ce	ells. The fusi	on cells express MHC			
13. ABSTRACT (Maximum 200 Work We have developed a vaclass I and II, costimulatory (FC/MUC1) prevented MC38	accine based on the fusions molecules and tumor-derive B/MUC1 tumor cell challenge	of DC with tumor ceed peptides, Immune and eradicated es	ization with o stablished MU	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary			
We have developed a vaclass I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transger	accine based on the fusions molecules and tumor-derive B/MUC1 tumor cell challenge nic mice (MUC1.Tg), In the p	of DC with tumor ce ed peptides, Immun e and eradicated es present study, MUC	ization with d stablished MU 1 transgenic	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with			
We have developed a vaclass I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transger strains that express polyoma	accine based on the fusions molecules and tumor-derive of the function of the	of DC with tumor ce ed peptides, Immun e and eradicated es present study, MUC riven by the mouse	ization with d stablished MU 1 transgenic mammary tu	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR)			
We have developed a vaclass I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgestrains that express polyoma promoter. The new breeder	accine based on the fusions molecules and tumor-derive B/MUC1 tumor cell challenge nic mice (MUC1.Tg). In the particular middle T antigen (MTag) decelors spontages	of DC with tumor ce ed peptides, Immun e and eradicated es present study, MUC riven by the mouse caneous mammary o	ization with o stablished MU 1 transgenic mammary tu carcinoma. V	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT			
We have developed a vaciles I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgestrains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age	ds) accine based on the fusions molecules and tumor-derive B/MUC1 tumor cell challenge nic mice (MUC1.Tg). In the particular middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages; of 4 weeks to 5 weeks. (iii)	of DC with tumor ce ed peptides, Immune e and eradicated es present study, MUC riven by the mouse aneous mammary of (i) latent stage from stage of carcinoma	ization with operation with the stablished MU transgenic mammary tubercinoma. Ver new born to formation fromation from the stablished fr	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT o 3 weeks old. (ii) m age of 6 weeks or older.			
We have developed a vaciles I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgestrains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age Immunization with DC/tumor	accine based on the fusions molecules and tumor-derive B/MUC1 tumor cell challenge nic mice (MUC1.Tg). In the particular middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages; of 4 weeks to 5 weeks. (iii) fusion cells in the premalig	of DC with tumor ceed peptides, Immune and eradicated espresent study, MUC riven by the mouse aneous mammary (i) latent stage from stage of carcinomanant stage rendered	ization with obtablished MU I transgenic mammary tucarcinoma. Von new born to formation from the 78% mi	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT of 3 weeks old. (ii) mage of 6 weeks or older, ce free of disease. These			
We have developed a vaciless I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgestrains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age Immunization with DC/tumor results match our hypothesis	accine based on the fusions molecules and tumor-derive B/MUC1 tumor cell challenge nic mice (MUC1.Tg). In the particular middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages: of 4 weeks to 5 weeks. (iii) fusion cells in the prematiges that immunization with fusion	of DC with tumor ceed peptides, Immune and eradicated espresent study, MUC riven by the mouse aneous mammary (i) latent stage from stage of carcinoma nant stage rendered on cells can general	ization with obtablished MU I transgenic mammary tucarcinoma. Von new born to formation from the 78% mi	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT of 3 weeks old. (ii) mage of 6 weeks or older, ce free of disease. These			
We have developed a vacilass I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgestrains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age Immunization with DC/tumor	accine based on the fusions molecules and tumor-derive B/MUC1 tumor cell challenge nic mice (MUC1.Tg). In the particular middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages: of 4 weeks to 5 weeks. (iii) fusion cells in the prematiges that immunization with fusion	of DC with tumor ceed peptides, Immune and eradicated espresent study, MUC riven by the mouse aneous mammary (i) latent stage from stage of carcinoma nant stage rendered on cells can general	ization with obtablished MU I transgenic mammary tucarcinoma. Von new born to formation from the 78% mi	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT of 3 weeks old. (ii) mage of 6 weeks or older, ce free of disease. These			
We have developed a vaciless I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgestrains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age Immunization with DC/tumor results match our hypothesis	accine based on the fusions molecules and tumor-derive B/MUC1 tumor cell challenge nic mice (MUC1.Tg). In the particular middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages: of 4 weeks to 5 weeks. (iii) fusion cells in the prematiges that immunization with fusion	of DC with tumor ceed peptides, Immune and eradicated espresent study, MUC riven by the mouse aneous mammary (i) latent stage from stage of carcinoma nant stage rendered on cells can general	ization with obtablished MU I transgenic mammary tucarcinoma. Von new born to formation from the 78% mi	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT of 3 weeks old. (ii) mage of 6 weeks or older, ce free of disease. These			
We have developed a vaciless I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgestrains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age Immunization with DC/tumor results match our hypothesis	accine based on the fusions molecules and tumor-derive B/MUC1 tumor cell challenge nic mice (MUC1.Tg). In the particular middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages: of 4 weeks to 5 weeks. (iii) fusion cells in the prematiges that immunization with fusion	of DC with tumor ceed peptides, Immune and eradicated espresent study, MUC riven by the mouse aneous mammary (i) latent stage from stage of carcinoma nant stage rendered on cells can general	ization with obtablished MU I transgenic mammary tucarcinoma. Von new born to formation from the 78% mi	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT of 3 weeks old. (ii) mage of 6 weeks or older, ce free of disease. These			
We have developed a vaciless I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgestrains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age Immunization with DC/tumor results match our hypothesis block the progression of presentation of presentations.	accine based on the fusions molecules and tumor-derive B/MUC1 tumor cell challenge nic mice (MUC1.Tg). In the particular middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages: of 4 weeks to 5 weeks. (iii) fusion cells in the prematiges that immunization with fusion	of DC with tumor ceed peptides, Immune and eradicated espresent study, MUC riven by the mouse aneous mammary (i) latent stage from stage of carcinoma nant stage rendered on cells can general	ization with obtablished MU I transgenic mammary tucarcinoma. Von new born to formation from the 78% mi	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT of 3 weeks old. (ii) mage of 6 weeks or older, ce free of disease. These			
We have developed a vaciless I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgestrains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age Immunization with DC/tumor results match our hypothesis	accine based on the fusions molecules and tumor-derive s/MUC1 tumor cell challenge in middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages: of 4 weeks to 5 weeks. (iii) fusion cells in the premalig s that immunization with fusionant lesion in MMT means and the stage of the sta	of DC with tumor ce ed peptides. Immune e and eradicated es present study, MUC riven by the mouse aneous mammary of (i) latent stage from stage of carcinoma nant stage rendered on cells can genera- ice.	ization with obtablished MU 1 transgenic mammary tucarcinoma. Von new born to formation from the 78% minute an effective	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT of 3 weeks old. (ii) mage of 6 weeks or older. ce free of disease. These we antitumor response to			
We have developed a vaclass I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgers trains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age Immunization with DC/tumor results match our hypothesis block the progression of president and the progression a	accine based on the fusions molecules and tumor-derive s/MUC1 tumor cell challenge in middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages: of 4 weeks to 5 weeks. (iii) fusion cells in the premalig s that immunization with fusionant lesion in MMT means and the stage of the sta	of DC with tumor ce ed peptides. Immune e and eradicated es present study, MUC riven by the mouse aneous mammary of (i) latent stage from stage of carcinoma nant stage rendered on cells can genera- ice.	ization with obtablished MU 1 transgenic mammary tucarcinoma. Von new born to formation from the 78% minute an effective	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT of 3 weeks old. (ii) mage of 6 weeks or older, ce free of disease. These we antitumor response to			
We have developed a vaciass I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgestrains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age Immunization with DC/tumor results match our hypothesis block the progression of predictic-tumor fusions, mammary carcinoma	accine based on the fusions molecules and tumor-derive s/MUC1 tumor cell challenge in middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages: of 4 weeks to 5 weeks. (iii) fusion cells in the premalig s that immunization with fusionant lesion in MMT means and the stage of the sta	of DC with tumor ce ed peptides. Immune e and eradicated es present study, MUC riven by the mouse aneous mammary of (i) latent stage from stage of carcinoma nant stage rendered on cells can genera- ice.	ization with obtablished MU 1 transgenic mammary tucarcinoma. Von new born to formation from the 78% minute an effective and effective an effective and effective	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT of 3 weeks old. (ii) mage of 6 weeks or older. ce free of disease. These we antitumor response to			
We have developed a vaclass I and II, costimulatory (FC/MUC1) prevented MC38 metastasis in MUC1 transgers strains that express polyoma promoter. The new breeder or MT mice form mammary of premalignant stage from age Immunization with DC/tumor results match our hypothesis block the progression of predictic-tumor fusions,	accine based on the fusions molecules and tumor-derive S/MUC1 tumor cell challenge nic mice (MUC1.Tg). In the particle middle T antigen (MTag) d (MMT mice) develops spont carcinoma with three stages: of 4 weeks to 5 weeks. (iii) fusion cells in the premaliges that immunization with fusion malignant lesion in MMT measurements.	of DC with tumor ceed peptides. Immune and eradicated espresent study, MUC riven by the mouse raneous mammary of (i) latent stage of carcinoma nant stage rendered on cells can generatice.	ization with catablished MU 1 transgenic mammary tucarcinoma. Van new born to formation from the 78% material effectives.	on cells express MHC dendritic/tumor fusion cells JC1-positve pulmonary mice are crossed with mor virus (MMTV-LTR) Ve demonstrate that MMT of 3 weeks old. (ii) m age of 6 weeks or older. ce free of disease. These we antitumor response to			

Table of Contents

Cover	.]
	.2
Table of Contents	3
Introduction	5
Body	5
Key Research Accomplishmen	ts ⁶
Reportable Outcomes	6
Conclusions	6
References	6&7
Appendices	

Prevention and Treatment of Spontaneous Mammary Carcinoma with Dendritic-tumor Fusion Cell Vaccine

Annual Report (USAMRAA)

Grant Number DAMA17-00-1-0220 (August 1, 2000 –June 1, 2001)

Jianlin Gong, M.D.

Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Harvard Medical School, Boston, MA 02115.

INTRODUCTION:

MUC1 transgenic mice are crossed with strains that express polyoma middle T antigen (MTag) driven by the mouse mammary tumor virus (MMTV-LTR) promoter. The new breeder (MMT mice) develops spontaneous mammary carcinoma. The proposed study develops a hybrid cell vaccine by fusing dendritic cells (DC) with MUC1 expressing carcinoma cells. Furthermore, the effectiveness of fusion cell vaccination in the prevention and treatment of spontaneous mammary carcinoma are investigated in MMT mice in which the mammary glands develop spontaneous carcinoma in a way similar to that of humans.

BODY:

1. Generation of MMT and MT mice

., The male Mtag mice are crossed with female MUC1.Tg mice to generate MMT mice. Routine polymerase chain reaction (PCR) is performed to identify the new born with expression of Mtag and MUC1 antigens. As a control, Mtag mice are crossed with wild-type C56BL/6 mice to generate mice expressing Mtag (MT). Both MMT and MT mice develop spontaneous mammary carcinomas.

Generation of MMT mice for experiment is a slow process since less than _ new breeders expressing both Mtag and MUC1 and only female mice are suitable for experiment.

2. Characterization of spontaneous mammary tumorigenesis in MMT and MT mice.

Groups of female MMT or MT mice (3 in each group) were sacrificed at age of 3, 4, 6, 8 and 10 weeks to determine the pattern of mammary carcinoma formation under microscope. At age of 3 weeks, very small mammary gland can be obtained. These glands look normal under microscope. At age of 4 weeks, the appearance of dysplasia of mammary epithelia was demonstrated. At age of 6 weeks or older, all the mice examined exhibited the formation of mammary carcinoma. These results indicate that MMT or MT mice form mammary carcinoma with three stages: (i) latent stage from new born to 3 weeks old. (ii) premalignant stage from age of 4 weeks to 5 weeks. (iii) stage of carcinoma formation from age of 6 weeks or older.

Female MMT or MT mice were palpated weekly starting at age of 6 weeks for tumor development. Most mice developed multiple and visible mammary carcinomas at age of 8 -10 weeks. The tumors progressed very rapidly. The mice become moribund about 16-20 weeks. There was no difference of mammary carcinoma development between MMT and MT mice.

3. Immunization with dendritic/tumor fusion cells stop progress of premiignant lesion into mammary carcinoma in MMT and MT mice.

In the first set of experiments, 18 MMT mice were immunized with FC/MUC1 (DC fused with MC38/MUC1 adenocarcinoma cell line) for four times starting at age of 30 days (mice in the premalignant stage), then the immunization was repeated every other week. Nine mice (50%) were survived up to 12 months free of disease.

To improve the effectiveness of vaccine, in the ongoing studies, DC were fused with carcinoma cells isolated from MMT mice. MMT mice (N=18) are immunized five times (at age of 30, 45, 60, 75 and 90 days) with DC/MMT tumor fusion cells. The mice are followed for 26-30 weeks now. Fourteen mice (78%) still survive free of disease. The mice will be followed for up to 12 months. These studies indicate that early vaccination with DC/MMT fusion cells prevents or stops the tumorigenesis process in MMT mice.

DISCUSSION:

We have developed a vaccine based on the fusions of DC with tumor cells. The fusion cells express MHC class I and II, costimulatory molecules and tumor-derived peptides. They are well equipped to activate T cells in the right environment (appendix 1). In our model, we demonstrate that immunization with DC/tumor fusion cells in the premalignant stage rendered the 78% mice free of disease. These results match our hypothesis that immunization with fusion cells can generate an effective antitumor response to block the progression of premalignant lesion in MMT mice.

In the coming year, we will continue the prevention and treatment of mammary carcinomas by DC/MMT or DC/MT fusion cell immunization in MMT or MT mice. We will immunize the MMT or MT mice in the latent stage (3 weeks old or younger) although it is technically challenge. In the treatment, considering the tumor burden, immunization with fusion cells will be combined with other antitumor agents or treatment modalities to enhance the antitumor effect.

CONCLUSIONS:

- 1. The tumorigenesis of MMT or MT mice has been characterized.
- 2. Immunization with DC/MMT fusion cells are effective to block the premalignant lesion progressing into mammary carcinoma.

PUBLICATIONS

1. Shigeo Koido, Yasuhiro Tanaka, Dongshu Chen and Jianlin Gong. The Kinetics of in Vivo Priming CD4 and CD8 T Cells by Dendritic/Tumor Fusion Cells in MUC1

Transgenic Mice. (Submitted for publication).

7